SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.

Oncotarget · 2016 · PMC5058712 · PMID 27095574

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a definite trendno p-value reported

Although there is a definite trend towards a decrease in these 2 parameters in saracatinib- compared to vehicle-treated myeloma-bearing mice, this did not reach significance.

also in 240 other papers

did not reach statistical significanceno p-value reported

In addition, Col1a1 expression was diminished, although this did not reach statistical significance.

also in 75,281 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.